Active, not recruitingPhase 2NCT05892068

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

Studying Hinman syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Andrew Seidman, MD, MD
Memorial Sloan Kettering Cancer Center
Intervention
Tucatinib(drug)
Enrollment
9 target
Eligibility
18 years · FEMALE
Timeline
20232028

Study locations (7)

Collaborators

Pfizer · Seagen Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05892068 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome

← Back to all trials